Cuscal (CCL) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
8 Jul, 2026Executive summary
NPAT for 1H FY26 rose 76% to $21.5m, with underlying NPAT up 13% to $24.2m and a margin of 15%, driven by strong operational growth and the completed Indue acquisition.
Transaction volume increased 9% year-over-year, reflecting continued strength across all core capabilities.
Indue acquisition completed on 1 December 2025 for $75.2m, contributing $5.3m to Net Operating Income and expected to deliver significant cost synergies and EPS accretion.
Interim dividend of 4.5 cents per share declared, fully franked, consistent with prior year.
Maintained a strong capital position, supporting ongoing integration and growth initiatives.
Financial highlights
Net operating income grew 10% year-over-year to $161.5m, including a $5.3m contribution from Indue.
Underlying NPAT increased 13% to $24.2m; statutory NPAT rose 76% to $21.5m.
EPS increased 4% to 12.6 cps, reflecting a higher share count post-IPO.
Operating expenses rose 10% to $127.5m, mainly due to higher employee costs and technology investment.
Underlying NPAT margin improved by 30 basis points to 15.0%.
Outlook and guidance
Full-year outlook raised: high-single-digit transaction volume growth expected to drive mid-teens underlying NPAT growth for FY26.
Indue integration expected to deliver over 20% return on invested capital and $15–20m in annual post-tax cost synergies by FY29, with $25–30m in integration costs over three years.
First half earnings projected to represent about 55% of full-year underlying NPAT, partly due to higher net interest income in H1.
Statutory EPS expected to be dilutive for the first two years post-acquisition due to integration timing.
Focus remains on product expansion, risk management, and Indue integration.
Latest events from Cuscal
- Pro forma NPAT up 42% to $21.5m, EBITDA up 21%, and transaction volumes up 7% in H1 FY25.CCL
H1 202528 May 2026 - FY25 NPAT beat forecasts; Indue acquisition to deliver major synergies and EPS growth.CCL
H2 202528 May 2026 - Profit up 21% to $31.6m, dividend increased, and IPO targeted for late 2024.CCL
H2 202425 Mar 2026 - Strong H1 FY25 growth and innovation position the business for further expansion.CCL
ASX SMIDcaps Conference Presentation8 Oct 2025